What is the minimum sample size required for tumor repertoire profiling?

Creative Biolabs can work with as little as tens of thousands of T cells from tumor tissue. With optimized amplification and sequencing workflows, even limited samples can generate informative repertoires. That said, higher cell yields improve coverage of the TCR landscape, allow better resolution of low-frequency clonotypes, and provide stronger statistical power for downstream analyses.

Can cryopreserved tumor samples be analyzed?

Yes. Creative Biolabs has validated protocols optimized for both frozen tumor tissues and cryopreserved PBMCs. While fresh material typically yields higher RNA integrity and repertoire coverage, cryopreserved samples can still generate robust datasets when processed with our optimized pipelines. This enables retrospective studies from biobanks or previously collected cohorts.

Are matched blood or control tissues required?

They are not mandatory, but their inclusion significantly enhances interpretability. Comparing tumor repertoires to matched blood or adjacent non-tumor tissue provides insights into tumor-specific clonotypes and immune reshaping. Such matched designs strengthen confidence in identifying disease-relevant TCR signatures versus systemic immune background.

How are clonotype expansions reported?

Expanded clonotypes are quantified using relative frequency, absolute counts, and diversity-adjusted measures. Creative Biolabs' reports highlight statistically significant expansions with visualization tools such as clonotype frequency plots, rank-abundance curves, and diversity indices. These outputs allow researchers to quickly distinguish dominant clones likely involved in tumor recognition from background noise.

Can results be integrated with other immunology datasets?

Absolutely. All clonotype and gene usage tables are delivered in exportable formats compatible with leading downstream platforms. This facilitates meta-analysis, integration with transcriptomics, or cross-study comparisons. Creative Biolabs also offers guidance on combining TCR data with multi-omics approaches for deeper biological insights.

Tumor associated TCR Repertoire Profiling Service

Services Platform Workflow Features Testimonials FAQ

Service Highlights

The immune system's ability to recognize and respond to tumor-associated antigens is largely mediated through T cell receptors (TCRs). Within the tumor microenvironment (TME), T cells undergo selective expansion, reshaping the repertoire in ways that can reflect anti-tumor immunity, immune suppression, or tumor escape. Profiling tumor-associated TCR repertoires is therefore essential for understanding immune surveillance, identifying clonotypes enriched in the TME, and linking repertoire changes with tumor biology.

At Creative Biolabs, we specialize in providing comprehensive TCR repertoire profiling services tailored to tumor-associated contexts. By combining advanced sequencing strategies, optimized laboratory protocols, and expert bioinformatics, Creative Biolabs enables researchers to deeply characterize the T cell landscape within tumors and matched controls. Our service is designed to empower basic research into tumor immunity and tumor-immune system interactions.

Service Highlights

Comprehensive profiling of tumor-infiltrating lymphocytes (TILs)

By analyzing TCR repertoires directly from tumor tissues, Creative Biolabs reveals clonal expansions that may represent tumor-reactive immune responses. This allows researchers to gain a deeper understanding of how T cells adapt to the tumor microenvironment.

Rigorous matched comparisons

Creative Biolabs' workflow enables side-by-side analysis of tumor samples, adjacent non-tumor tissues, and peripheral blood. This comparative design uncovers repertoire shifts unique to the tumor setting, strengthening the reliability of conclusions.

High-sensitivity detection of expanded clonotypes

Even in complex tumor tissues with low T cell yield, Creative Biolabs' optimized sequencing strategies capture rare and dominant clones with confidence, providing insight into potential immune surveillance mechanisms.

Detailed diversity and clonality metrics

From Shannon and Simpson indexes to clonality distribution curves, Creative Biolabs delivers quantitative indicators that reveal how repertoire diversity is reshaped by tumor-associated pressures.

If you are interested in exploring how these highlights can be tailored to your project, our team is available for direct consultation.

Technology Foundation

Creative Biolabs integrates a robust sequencing and computational platform:

Next-generation sequencing (NGS): High-throughput coverage of tumor-associated TCRs.
Targeted primer sets: Optimized for capturing α and β chain repertoires in complex tissue samples.
Bias-reducing amplification strategies: Designed to minimize skew and ensure accurate representation of clonotype frequencies.
Standardized annotation: Alignment to reference databases such as IMGT for consistent gene segment identification.
Advanced analytics: Proprietary pipelines developed at Creative Biolabs provide deep clonotype clustering, comparative analyses, and export-ready datasets for integration with other immunological studies.

Creative Biolabs' team is available to explain how these layers can enhance your tumor immunology projects.

Stepwise Workflow

Step 1. Sample Collection and Evaluation
Creative Biolabs accepts a range of tumor-associated sample types, including:
- Tumor-infiltrating lymphocytes (TILs)
- Fresh or cryopreserved tumor tissue suspensions
- Matched peripheral blood mononuclear cells (PBMCs)
- Adjacent non-tumor tissue as control
Initial evaluation assesses cell viability, sample integrity, and T cell frequency to confirm suitability for repertoire sequencing.
Inquire with us
Step 2. T Cell Enrichment from Tumor Samples
To increase sensitivity in challenging tumor tissues, Creative Biolabs applies enrichment strategies such as:
- Surface marker-based isolation:
  CD3+ or subset-specific enrichment.
- TIL-focused protocols:
  Optimized for fibrotic or low-yield tumor tissues.
- Comparative enrichment:
  Optional parallel isolation of CD4⁺ and CD8⁺ T cell fractions.
Inquire with us
Step 3. Nucleic Acid Preparation

From enriched cells, RNA or DNA is isolated under low-input protocols adapted to tumor materials. Both RNA and DNA workflows are available depending on whether expressed TCRs or stable repertoire coverage is desired.
Inquire with us
Step 4. Library Construction

Libraries are prepared using carefully designed primers to capture V(D)J rearrangements across α and β chains. Redundancy-reducing strategies are incorporated to ensure high-fidelity recovery of rare as well as expanded clonotypes.
Inquire with us
Step 5. Sequencing Execution

Libraries undergo deep sequencing on short-read NGS platforms. Sequencing depth is tailored to tumor-associated contexts, allowing comprehensive coverage of clonotypes present even at low frequency.
Inquire with us
Step 6. Bioinformatics and Repertoire Analysis
Creative Biolabs' proprietary computational workflow delivers:
- Identification of V and J gene segment usage.
- Construction of clonotype tables with frequency and abundance data.
- Diversity metrics.
- Comparative analysis between tumor, periphery, and control samples.
- Clonal tracking across different tumor regions or experimental groups.
Inquire with us

Why Choose Creative Biolabs?

Tumor-specialized expertise

Unlike generalized repertoire services, Creative Biolabs has protocols optimized specifically for tumor-associated materials, addressing challenges like low T cell yield and sample heterogeneity.

Flexible input acceptance

Whether working with fresh tumor digests, frozen samples, or matched blood, Creative Biolabs customizes protocols for each project's needs.

Comprehensive analytics

Our pipelines go beyond clonotype recovery, integrating tumor-specific diversity and expansion metrics.

Research-focused reliability

Creative Biolabs' services are designed for fundamental research use, ensuring consistent and reproducible datasets trusted by academic groups and research institutes worldwide.

To explore how these advantages can support your research group, contact us for a tailored consultation.

Feedback from Research Partners

"Working with Creative Biolabs gave us clarity into the tumor-infiltrating TCR repertoire. The level of detail and comparative analysis far exceeded what we expected."

– Academic Research Scientist

"Their team understood the specific challenges of tumor-associated T cell profiling and tailored every step to maximize our success."

– Postdoctoral Fellow

Connect with Creative Biolabs to join our growing network of satisfied research collaborators.

Understanding tumor-associated TCR repertoires opens the door to fundamental discoveries about immune recognition, tumor escape mechanisms, and the biology of the tumor microenvironment. Creative Biolabs' Tumor Associated TCR Repertoire Profiling Service combines optimized laboratory protocols, rigorous sequencing, and advanced analytics to provide researchers with reliable, high-resolution insights. By partnering with Creative Biolabs, you can move beyond raw data toward meaningful biological interpretation that strengthens your research outcomes. Contact us to discuss your project.

Frequently Asked Questions

Q: What is the minimum sample size required for tumor repertoire profiling?
A: Creative Biolabs can work with as little as tens of thousands of T cells from tumor tissue. With optimized amplification and sequencing workflows, even limited samples can generate informative repertoires. That said, higher cell yields improve coverage of the TCR landscape, allow better resolution of low-frequency clonotypes, and provide stronger statistical power for downstream analyses.
Q: Can cryopreserved tumor samples be analyzed?
A: Yes. Creative Biolabs has validated protocols optimized for both frozen tumor tissues and cryopreserved PBMCs. While fresh material typically yields higher RNA integrity and repertoire coverage, cryopreserved samples can still generate robust datasets when processed with our optimized pipelines. This enables retrospective studies from biobanks or previously collected cohorts.
Q: Are matched blood or control tissues required?
A: They are not mandatory, but their inclusion significantly enhances interpretability. Comparing tumor repertoires to matched blood or adjacent non-tumor tissue provides insights into tumor-specific clonotypes and immune reshaping. Such matched designs strengthen confidence in identifying disease-relevant TCR signatures versus systemic immune background.
Q: How are clonotype expansions reported?
A: Expanded clonotypes are quantified using relative frequency, absolute counts, and diversity-adjusted measures. Creative Biolabs' reports highlight statistically significant expansions with visualization tools such as clonotype frequency plots, rank-abundance curves, and diversity indices. These outputs allow researchers to quickly distinguish dominant clones likely involved in tumor recognition from background noise.
Q: Can results be integrated with other immunology datasets?
A: Absolutely. All clonotype and gene usage tables are delivered in exportable formats compatible with leading downstream platforms. This facilitates meta-analysis, integration with transcriptomics, or cross-study comparisons. Creative Biolabs also offers guidance on combining TCR data with multi-omics approaches for deeper biological insights.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: